Introduction
Materials and methods
Clinical samples collection
Tissue microarray (TMA) and immunohistochemistry (IHC)
Cell culture and transfection
RNA isolation and real-time quantitative PCR (qRT-PCR)
Western blotting (WB) assay
Cell proliferation and colony formation assay
Cell cycle determination
Transwell migration and invasion assay
Tumor xenograft in vivo experiments
RNA stability determination
RNA immunoprecipitation (RIP)
Library preparation and transcriptome sequencing
Dual-luciferase reporter assay
Glucose consumption, lactate secretion, and ATP concentration measurement
Bioinformatics analysis of in silico database
Statistical analysis
Results
Expression profile of Spectrin-family genes in ccRCC
SPTBN1 expression was down-regulated in ccRCC
SPTBN1 down-regulation predicted an unfavorable survival of ccRCC patients
Characteristics | Low expression of SPTBN1 | High expression of SPTBN1 | P-Value |
---|---|---|---|
Total | 269 | 270 | |
Age (%) | 0.043 | ||
< = 60 | 122 (22.6%) | 147 (27.3%) | |
> 60 | 147 (27.3%) | 123 (22.8%) | |
Gender (%) | 0.002 | ||
Female | 75 (13.9%) | 111 (20.6%) | |
Male | 194 (36%) | 159 (29.5%) | |
Stage (%) | < 0.001 | ||
Stage I | 102 (19%) | 170 (31.7%) | |
Stage II | 32 (6%) | 27 (5%) | |
Stage III | 75 (14%) | 48 (9%) | |
Stage IV | 58 (10.8%) | 24 (4.5%) | |
T stage (%) | < 0.001 | ||
T1 | 106 (19.7%) | 172 (31.9%) | |
T2 | 42 (7.8%) | 29 (5.4%) | |
T3 | 113 (21%) | 66 (12.2%) | |
T4 | 8 (1.5%) | 3 (0.6%) | |
N stage (%) | 0.124 | ||
N0 | 125 (48.6%) | 116 (45.1%) | |
N1 | 12 (4.7%) | 4 (1.6%) | |
M stage (%) | < 0.001 | ||
M0 | 199 (39.3%) | 229 (45.3%) | |
M1 | 55 (10.9%) | 23 (4.5%) |
Characteristics | Total(N) | Odds Ratio (OR) | P-Value |
---|---|---|---|
Age (> 60 vs. < = 60) | 539 | 0.694 (0.494–0.974) | 0.035 |
Gender (male vs. female) | 539 | 0.554 (0.385–0.793) | 0.001 |
T stage (T2&T3&T4 vs. T1) | 539 | 0.371 (0.261–0.524) | < 0.001 |
N stage (N1 vs. N0) | 257 | 0.359 (0.098–1.064) | 0.083 |
M stage (M1 vs. M0) | 506 | 0.363 (0.212–0.605) | < 0.001 |
Stage (stage III&IV vs. stage I&II) | 536 | 0.368 (0.256–0.527) | < 0.001 |
Characteristics | Number of cases | SPTBN1 expression | P-Value | |
---|---|---|---|---|
Low | High | |||
Total | 180 | 106 | 74 | |
Age(years) | ||||
< 65 | 103 | 61 | 42 | 0.916 |
≥ 65 | 77 | 45 | 32 | |
Gender | ||||
Male | 99 | 58 | 41 | 0.927 |
Female | 81 | 48 | 33 | |
T stage | ||||
T1–T2 | 110 | 52 | 58 | < 0.001 |
T3–T4 | 70 | 54 | 16 | |
Histological grade | ||||
I–II | 78 | 32 | 46 | < 0.001 |
III–IV | 102 | 74 | 28 | |
Tumor size(cm) | ||||
< 4 | 115 | 51 | 64 | < 0.001 |
≥ 4 | 65 | 55 | 10 | |
Survival State | ||||
Alive | 119 | 60 | 59 | 0.034 |
Dead | 37 | 26 | 11 | |
Recurrence | ||||
Yes | 28 | 21 | 7 | 0.020 |
No | 128 | 65 | 63 | |
GPT2 protein expression level | ||||
High | 99 | 67 | 32 | 0.008 |
Low | 81 | 39 | 42 |